What is MOKSHA8 PHARMACEUTICALS?
Founded in 2007 and headquartered in Berwyn, Pennsylvania, Moksha8 Pharmaceuticals operates as a specialized commercialization platform focused on the Latin American pharmaceutical sector. The company distinguishes itself through a commitment to best-in-class operational excellence and strict adherence to FCPA compliance, which serves as a critical differentiator in the regional market. By acting as a strategic partner for global pharmaceutical entities, Moksha8 facilitates the entry and distribution of CNS products and other therapeutic categories into complex markets. Its business model leverages deep local expertise to manage the entire commercial lifecycle, ensuring that international pharmaceutical standards are maintained while addressing the specific needs of Latin American healthcare providers and patients.
How much funding has MOKSHA8 PHARMACEUTICALS raised?
MOKSHA8 PHARMACEUTICALS has raised a total of $219.1M across 4 funding rounds:
Series A
$39M
Series B
$25.1M
Series C
$30M
Unspecified
$125M
Series A (2008): $39M with participation from TPG Biotech
Series B (2009): $25.1M led by Montreux Equity Partners
Series C (2010): $30M supported by Watson
Unspecified (2012): $125M featuring Forest Laboratories
Key Investors in MOKSHA8 PHARMACEUTICALS
Forest Laboratories
A former major pharmaceutical entity known for licensing and commercializing European drug portfolios for the North American market prior to its acquisition by Actavis.
TPG Biotech
The life sciences venture capital arm of TPG, focusing on early-to-late stage investments in companies developing innovative medical technologies and therapeutics.
Montreux Equity Partners
A private equity firm specializing in growth-stage investments within the healthcare and life sciences sectors, providing capital to companies with high commercial potential.
What's next for MOKSHA8 PHARMACEUTICALS?
Looking ahead, Moksha8 is positioned to leverage its established infrastructure to further penetrate the Latin American market. The recent capital allocation is expected to bolster the company's commercial reach and support the expansion of its existing alliances with global pharmaceutical leaders. As the firm continues to refine its operational model, the focus will likely shift toward optimizing supply chain efficiencies and expanding its therapeutic footprint. By maintaining its reputation for compliance and operational integrity, Moksha8 remains a primary candidate for further strategic collaborations, potentially serving as the gateway for additional international firms seeking to navigate the regulatory and logistical hurdles of the Latin American pharmaceutical landscape. The company's ability to sustain long-term growth will depend on its continued agility in responding to evolving regional healthcare policies and market demands.
See full MOKSHA8 PHARMACEUTICALS company page
